Rituxsanbe Dosage/Direction for Use

Low-grade or Follicular Non-Hodgkin's Lymphoma: lnitial treatment: Intravenous Monotherapy: The recommended dosage of RITUXSANBE used as monotherapy for adult patients is 375 mg/m² body surface area (BSA), administered as an IV Infusion once weekly for four weeks.
Intravenous Combination therapy: The recommended dosage of RITUXSANBE in combination with any chemotherapy is 375 mg/m² BSA per cycle for a total of: a) 8 cycles with R-CVP (21 days/cycle); b) 8 cycles with R-MCP (28 days/cycle); c) 8 cycles with R-CHOP (21 days/cycle); 6 cycle if a complete remission is achieved after 4 cycles; d) 6 cycles with R-CHVP-interferon (21 days/cycle).
RJTUXSANBE should be administered on day 1 of each chemotherapy cycle after IV administration of the Glucocorticoid component of the chemotherapy, if applicable.
Retreatment following relapse in Non-Hodgkin's Lymphoma: Patients who have responded to RITUXSANBE initially have been treated again with RITUXSANBE at a dose of 375 mg/m² BSA, administered as an IV infusion once weekly for four weeks.
Maintenance treatment: Previously untreated patients after response to induction treatment may receive maintenance therapy with RITUXSANBE given at 375 mg/m² BSA once every 2 months until disease progression or for a maximum period two years (12 infusion) Relapsed/refractory patients after response to induction treatment may receive maintenance therapy with RITUXSANBE given at 375 mg/m² BSA once every 3 months until disease progression or for a maximum period two years.
Diffuse large B-cell Non-Hodgkin's Lymphoma: RITUXSANBE should be used in combination with CHOP chemotherapy. The recommended dosage of RITUXSANBE is 375 mg/m² BSA, administered on day1 of each chemotherapy cycle for 8 cycles after IV administration of the Glucocorticoid component of CHOP. Safety and efficacy of RITUXSANBE have not been established in combination with other chemotherapy.
Special Dosage Instruction: Children and adolescents: RITUXSANBE is not recommended for use in children due to lack of data on safety and efficacy.
Elderly: No dose adjustment is required in elderly patients (Age > 65 years).